Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.
Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. operates as a pharmaceutical technology research and development and services company in China. The company primarily provides drug research and development services; and the transformation of research and development technology results for various pharmaceutical, as well as pharmaceutical research and development investment companies. Its business cove… Read more
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. - Asset Resilience Ratio
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096) has an Asset Resilience Ratio of 3.84% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2024–2024)
This chart shows how Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.'s Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥148.64 Million | 3.84% |
| Total Liquid Assets | CN¥148.64 Million | 3.84% |
Asset Resilience Insights
- Limited Liquidity: Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. maintains only 3.84% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. Industry Peers by Asset Resilience Ratio
Compare Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Zhejiang Int'L Group Co Ltd
SHE:000411 |
Drug Manufacturers - General | 0.00% |
|
Zhejiang Zhenyuan Share Co Ltd
SHE:000705 |
Drug Manufacturers - General | 5.75% |
|
Hunan Jingfeng Pharmaceutical
SHE:000908 |
Drug Manufacturers - General | 0.38% |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952 |
Drug Manufacturers - General | 5.37% |
|
Zhejiang Haisen Pharmaceutical Co. Ltd. A
SHE:001367 |
Drug Manufacturers - General | 32.14% |
|
Yifan Xinfu Pharmaceutical Co Ltd
SHE:002019 |
Drug Manufacturers - General | 0.53% |
|
Guangdong Jiaying Pharmaceutical Co Ltd
SHE:002198 |
Drug Manufacturers - General | 0.00% |
|
PharmGen Science Inc
KO:004720 |
Drug Manufacturers - General | 0.16% |
Annual Asset Resilience Ratio for Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (2024–2024)
The table below shows the annual Asset Resilience Ratio data for Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 2.23% | CN¥83.00 Million | CN¥3.72 Billion | -- |